ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy | ALK

ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy

Link

https://www.globenewswire.com/news-release/2026/04/20/3277007/0/en/ALK-announce…

Created date

Mon, 04/20/2026 - 12:00

Nasdaq ID

3277007

Last updated: 20.04.2026